On February 9, 2022 NeoImmuneTech, Inc. (KOSDAQ: 950220), a clinical-stage T cell-focused biopharmaceutical company, reported that its Chief Business Officer, Sam Zhang, Ph.D., MBA, will present at the upcoming BIO CEO and Investor Conference, to be held February 14-17 in New York, NY (Press release, NeoImmuneTech, FEB 9, 2022, View Source [SID1234607930]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Additionally, Dr. Zhang was invited as a speaker on the panel "Maximize Your Asset’s Potential Value for Deal Making" at the Fierce BD&L Summit for Life Sciences, to be held March 15-16 in San Francisco, CA, where he will present "NT-I7 Strategic Positioning via Clinical Collaborations with Global I-O Leaders" as a case study. Subsequently, he will join a panel discussion titled "Getting your House in Order: Strategies for Sellers to Best Prepare for a Diligence Review".
The details of the company’s presentations are as follows:
BIO CEO and Investor Conference
Date: Tuesday, February 15th, 2022
Time: 11:15am ET
Website: BIO CEO & Investor Conference | BIO
Fierce BD&L Summit for Life Sciences
Date: Wednesday, March 16th, 2022
Time: 9:30am PT (case study), 9:45am PT (panel discussion)
Website: Agenda | BDL Summit
About NT-I7
NT-I7 (efineptakin alfa) is the only clinical-stage long-acting human IL-7, and is being developed for oncologic and immunologic indications, in which T cell amplification and enhanced functionality may provide clinical benefit. IL-7 is a fundamental cytokine for naïve and memory T cell development and for sustaining immune response to chronic antigens (as in cancer) or foreign antigens (as in infectious diseases). In clinical trials to date, NT-I7 has exhibited favorable PK/PD and safety profiles, both as a monotherapy and in combination with other anticancer treatments. NT-I7 is being studied in multiple clinical trials in solid tumors and as a vaccine adjuvant. Studies are being planned for testing in hematologic malignancies, additional solid tumors and other immunology-focused indications.